To describe a case of culture-proven multidrug-resistant tuberculous (MDR-TB) meningitis, in which the patient survived long enough for clinicians to adjust antituberculous therapy to second-line therapeutic agents.
DESIGN:
Case report.
SETTING:
Tertiary care hospital.
PATIENT:
Twenty-one-month-old girl with MDR-TB meningitis.
INTERVENTIONS:
Initial standard treatment failed. Subsequent treatment with second-line therapeutic agents including ciprofloxacin, cycloserine, ethambutol, ethionamide, and rifabutin were given for approximately two years. Concentrations of these drugs were measured in serum and cerebrospinal fluid in the presence and absence of meningeal inflammation.
MAIN OUTCOME MEASURES/RESULTS:
The patient survived for approximately two years after initiation of second-line anti-TB therapy. During this treatment, she developed a ventriculo-peritoneal shunt tunnel tract infection secondary to MDR-TB.
CONCLUSIONS:
All TB meningitis isolates for which the source case antibiotic susceptibility pattern is not known should be cultured and susceptibility tested using rapid broth techniques. Measurement and subsequent adjustment of therapeutic drug concentrations may optimize therapy with second-line anti-TB drugs in TB meningitis. Better pediatric formulations and pharmacokinetic data for second-line and anti-TB therapeutic agents are needed.
Pablos-MendezARaviglioneMCLaszloABinkinNRiederHLBustreoFGlobal surveillance for antituberculosis-drug resistance, 1994–1997. World Health Organization–International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med1998;338: 1641–9.
2.
GobleMIsemanMDMadsenLAWaiteDAckersonLHorsburghCR. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med1993;328: 527–32.
3.
KilpatrickMEGirgisNIYassinMWAbuElEllaAA. Tuberculous meningitis — Clinical and laboratory review of 100 patients. J Hyg1986;96: 231–8.
4.
VisudhiphanPChiemchanyaS. Tuberculous meningitis in children: Treatment with isoniazid and rifampicin for twelve months. J Pediatr1989;114: 875–9.
5.
SumayaCVSimekMSmithMHSeidemannMFFerrissGSRubinW. Tuberculous meningitis in children during the isoniazid era. J Pediatr1975;87: 43–9.
6.
JacobsRFSunakornPChotpitayasunonahTPopeSKelleherK. Intensive short course chemotherapy for tuberculous meningitis. Pediatr Infect Dis J1992;11: 194–8.
7.
WaeckerNJConnorJD. Central nervous system tuberculosis in children: A review of 30 cases. Pediatr Infect Dis J1990;9: 536–43.
8.
PeloquinCA. Antituberculosis drugs: Pharmacokinetics. In: HeifetsLB, ed. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press, 1991: 59–65.
9.
BerenguerJMorenoSLagunaFVicenteTAdradosMOrtegaATuberculous meningitis in patients infected with the human immunodeficiency virus. N Engl J Med1992;326:668–72.
10.
HornDLHewlettDPetersonSSabidoDOpalSM. RISE-resistant tuberculous meningitis in AIDS patient. Lancet1993;341: 177–8.
11.
Centers for Disease Control. Multi-drug resistant tuberculosis — North Carolina. MMWR Morbid Mortal Wkly Rep1987;35 (51–52):785–7.
12.
WattGSelkonJBBautistaSLaughlinLW. Drug resistant tuberculous meningitis in the Philippines: Report of a case. Tubercle1989;70: 139–41.
13.
PeloquinCA. Pharmacology of the antimycobacterial drugs. Med Clin North Am1993;77: 1253–62.
14.
Centers for Disease Control and Prevention. Management of persons exposed to multidrug-resistant tuberculosis. MMWR Morbid Mortal Wkly Rep1992;41 (RR-11):61–71.
15.
HobbyGLJohnsonPMCrawford-GagliardiLGreethamLLenertTF. Primary drug resistance: A continuing study of tubercle bacilli in a veteran population within the United States. IV. Factors influencing the observed frequency of resistance. Am Rev Respir Dis1965;91: 575–82.
16.
DonaldPRMalanC. Cerebrospinal fluid lactate and lactate dehydrogenase activity in the rapid diagnosis of bacterial meningitis. S Afr Med J1986;69: 39–42.
17.
CarliniSMBeyersNSchoemanJFNelEDTruterEJDonaldPR. Adenylate kinase activity in the cerebrospinal fluid of children with tuberculous meningitis and its relationship to neurological outcome. Scand J Infect Dis1997;29: 275–80.
18.
CoovadiaYMDawoodAEllisMECoovadiaHMDanielTM. Evaluation of adenosine deaminase activity and antibody to Mycobacterium tuberculosis antigen 5 in cerebrospinal fluid and the radioactive bromide partition test for the early diagnosis of tuberculosis meningitis. Arch Dis Child1986;61: 428–35.
19.
RiberaEVazquezJM MartinezOcanaISeguraRMPascualC. Activity of adenosine deaminase in cerebrospinal fluid for the diagnosis and follow-up of tuberculous meningitis in adults. J Infect Dis1987;155: 603–7.
20.
NozakiHFukuuchiYKotoATanakaKKobariM. Time-course of adenosine deaminase activity in the cerebrospinal fluid in patients with tuberculous meningitis (Japanese). Kekkaku1994;69: 663–70.
21.
ShankarPManjunathNMohanKKPrasadKBehariM ShriniwasRapid diagnosis of tuberculous meningitis by polymerase chain reaction. Lancet1991;337:5–7.
22.
ZhangYHeymBAllenBYoungDColeS. The catalase–peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature1992;358: 591–3.
23.
TelentiAImbodenPMarchesiFLowrieDColeSColstonJMDetection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet1993;341:647–50.
24.
PearsonMLJerebJAFriedenTRCrawfordJTDavisBJDooleySWNosocomial transmission of multidrug-resistant Mycobacterium tuberculosis. Ann Intern Med1992;117:191–6.
25.
EllardGAHumphriesMJAllenBW. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. Am Rev Respir Dis1993;148: 650–5.
26.
PeloquinCAHenshawTLHuittGABerningSENittaATJamesGT. Pharmacokinetic evaluation of p-aminosalicylic acid granules. Pharmacotherapy1994;14: 40–6.
27.
PeloquinCABulpittAEJareskoGSJelliffeRWChildsJMNixDE. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother1999;43: 568–72.
28.
NarangPKLewisRCBianchineJR. Rifabutin absorption in humans: Relative bioavailability of food effect. Clin Pharmacol Ther1992;52: 335–41.
29.
McEvoyGK, ed. AHFS drug information 1999. Bethesda, MD: American Society of Health-Systems Pharmacists, 1999.
30.
American Academy of Pediatrics Report of the Committee on Infectious Diseases. Tuberculosis. In: PeterG, ed. 1997 Red book. Elk Grove Village, IL: American Academy of Pediatrics, 1997: 494–5.
31.
DonaldPRSeifartHI. Cerebrospinal fluid concentrations of ethionamide in children with tuberculous meningitis. J Pediatr1989;115: 483–6.
32.
HeifetsLB. Antituberculosis drugs: Antimicrobial activity in vitro. In: HeifetsLB, ed. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press, 1991: 13–58.
